Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Rhabdomyosarcoma × Doxorubicin × Clear all

Phase

Phase 3 5 Phase 2 4 Phase 1 2 Phase EARLY_PHASE1 1 Phase 4 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 20 Breast Neoplasms 17 Lymphoma 12 Sarcoma 11 Lymphoma, Non-Hodgkin 9 Lymphoma, B-Cell 7 Lymphoma, Follicular 6 Hodgkin Disease 6 Lymphoma, Mantle-Cell 5 Immunoblastic Lymphadenopathy 5 Ovarian Neoplasms 4 Neoplasms 4 Lymphoma, Large-Cell, Anaplastic 4 Leukemia, Lymphocytic, Chronic, B-Cell 4 Carcinoma, Hepatocellular 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Multiple Myeloma 3 Lymphoma, T-Cell, Peripheral 3 Lymphoma, Primary Effusion 3 Chondrosarcoma 3 Triple Negative Breast Neoplasms 2 Solitary Fibrous Tumors 2 Sarcoma, Clear Cell 2 Recurrence 2 Plasmablastic Lymphoma 2 Osteosarcoma 2 Neoplasm Metastasis 2 Lymphoma, T-Cell 2 Lymphoma, B-Cell, Marginal Zone 2 Liver Neoplasms 2

Interventions

Temozolomide 8 Irinotecan 7 Vincristine 6 Nivolumab 2 temsirolimus 1 talazoparib 1 surufatinib 1 silmitasertib 1 regorafenib 1 prexasertib 1 pegylated granulocyte colony-stimulating factor 1 pegfilgrastim 1 liposomal doxorubicin 1 lenvatinib 1 lentiviral minigene vaccine of COVID-19 coronavirus 1 irinotecan sucrosofate 1 ganitumab 1 eribulin 1 efineptakin alfa 1 dostarlimab 1 dinutuximab 1 copanlisib 1 bempegaldesleukin 1 atezolizumab 1 adavosertib 1 abemaciclib 1 Zoledronic Acid 1 Vinorelbine 1 Thrombopoietin 1 Receptor Protein-Tyrosine Kinases 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04625907 2024-05-23

FaR-RMS

University of Birmingham

Phase 1/2 Recruiting

Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡